"4 years following radiation therapy, there is a 25% lower hazard of bowel disorders and a 46% lower hazard of related procedures [in patients who received a spacer],” says Michael R. Folkert, MD, PhD.
Michael R. Folkert, MD, PhD
Advertisement
Articles by Michael R. Folkert, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
Study shows durable 3-year outcomes with first-line gemcitabine/docetaxel in NMIBC
2
Experts discuss the challenge of detecting CIS in bladder cancer
3
Kathryn Gessner, MD, PhD, on the challenges of selecting patients for bladder preservation
4
Phase 3 trial launches of CAIX-targeted radiopharmaceutical for ccRCC
5